Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer [Internet].

Black ER, Falzon L, Aronson N.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec.


Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.


Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.

Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S.

Cancer Prev Control. 1997 Dec;1(5):379-92.


A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):282-308. Review.


Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.


Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.

Ishiguro M, Mochizuki H, Tomita N, Shimada Y, Takahashi K, Kotake K, Watanabe M, Kanemitsu Y, Ueno H, Ishikawa T, Uetake H, Matsui S, Teramukai S, Sugihara K.

BMC Cancer. 2012 Jul 7;12:281.


Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.

Potosky AL, O'Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, Ekezue BF, Selvam N, Kessler LG, Zhou Y, Schwartz MD.

Cancer. 2015 Nov 15;121(22):4062-70. doi: 10.1002/cncr.29621. Epub 2015 Aug 20.


American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG.

J Clin Oncol. 2004 Aug 15;22(16):3408-19. Epub 2004 Jun 15. Review.


Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis.

Lu AT, Salpeter SR, Reeve AE, Eschrich S, Johnston PG, Barrier AJ, Bertucci F, Buckley NS, Salpeter EE, Lin AY.

Clin Colorectal Cancer. 2009 Oct;8(4):207-14. doi: 10.3816/CCC.2009.n.035. Review.


Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.


Patients' perceptions of gene expression profiling in breast cancer treatment decisions.

Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA.

Curr Oncol. 2014 Apr;21(2):e203-11. doi: 10.3747/co.21.1524.


Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.

Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA.

Breast Cancer Res Treat. 2011 Nov;130(2):619-26. doi: 10.1007/s10549-011-1628-6. Epub 2011 Jun 17.


Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].

Lin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov.


Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.

Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B.

Acta Oncol. 2015 Jan;54(1):5-16. doi: 10.3109/0284186X.2014.975839. Epub 2014 Nov 28. Review.


Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.

Yang M, Rajan S, Issa AM.

Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22.


Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A.

Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23.


Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.

Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO Jr, Goodman KA, Keating NL.

J Oncol Pract. 2014 Sep;10(5):e360-7. doi: 10.1200/JOP.2013.001309. Epub 2014 Jul 1.


Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?

Kelley RK, Venook AP.

Clin Colorectal Cancer. 2011 Jun;10(2):73-80. doi: 10.1016/j.clcc.2011.03.001. Epub 2011 Apr 22. Review.

Supplemental Content

Support Center